Lan Zhang
Guan Wang
Lingjuan Zhu
Wei Wei
Jin Zhang- 1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China
- 2State Key Laboratory of Biotherapy and Cancer Center, Nursing Key Laboratory of Sichuan Province, Innovation Center of Nursing Research, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China
- 3Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
- 4Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, United States
- 5School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
Editorial on the Research Topic
Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy
Cancer is often rendered an uncurable disease, which poses a great threat to human health worldwide. Among all kinds of cancers, gynecological cancers (including breast, ovarian, cervical, and endometrial cancer) and gastrointestinal cancers (including gastric, colorectal, liver, and pancreatic cancer) are the most common cancer types worldwide (Ciou et al., 2022; Murphy et al., 2018). Although chemotherapy, radiotherapy, and surgical excision are commonly used to treat these gynecological and gastrointestinal cancers, cancer cells frequently develop resistance to conventional cancer therapy due to a variety of mechanisms (Davern et al., 2020; Marchetti et al., 2021). Accordingly, new therapeutic strategies such as the identification of novel potential molecular targets or biomarkers, as well as the development of new molecular diagnostic approaches and targeted therapy (e.g., proteins, transcription factors, non-coding RNA, targeted small-molecule drugs, etc.) are greatly needed to overcome inherent and acquired resistance, which would provide a promising therapeutic approach for the treatment of various gynecological and gastrointestinal cancers.
Breast cancer is the most common global malignancy and one of the most serious gynecological cancers affecting women, which also represents currently a top biomedical research priority (Akram et al., 2017). And its incidence and mortality rates are expected to increase continuously the next years (Barzaman et al., 2020). Accumulating evidence suggests that circular RNAs (circRNAs) are highly correlated with tumor progression and pathogenesis in breast cancer (Sang et al., 2019). Whereas, their regulatory roles and corresponding mechanisms in breast cancer are still unknown to some extent. Therefore, Lin et al. explored the circRNA-mediated competive endogenous RNA (ceRNA) network to uncover the possible roles and clinical implications of circRNAs in breast cancer. Through functional experiments, they found that the depletion of two circRNAs, circ_0008812 and circ_0001583, could significantly inhibit the proliferation of MCF-7 cells, providing a new perspective into the molecular mechanisms of breast cancer pathogenesis.
Pancreatic adenocarcinoma (PAAD) is the most common primary malignancy of the pancreas and is a highly aggressive tumor that is almost uniformly lethal in humans (Ge et al., 2022). According to previous research, the APOBEC family is associated with development of a variety of cancers (Mertz et al., 2022). Duan et al. discovered that APOBEC1/3A/3G/3H showed significantly elevated expression in PAAD than para-cancerous or normal tissues, indicating they have the potential to serve as novel biomarkers or therapeutic targets. Furthermore, recent evidence uncovered by Duan et al. suggests that SUMO family member is closely related to the occurrence and development of PAAD, which can also be used as a new biomarker and therapeutic target for patients with PAAD.
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths in the world (Dekker et al., 2019). In addition, the incidence of CRC is increasing continuously in some areas of the world (Issa et al., 2017). Yunos et al. identified specific druggable somatic mutations by using the whole-genome sequencing approach on Malaysian patients, which could be of great benefit especially to Malaysian CRC patients. To note, at least one druggable somatic alteration was identified in 88% of the Malaysian CRC patients. Among them were two frameshift mutations in RNF43 (G156fs and P192fs) predicted to have responsive effects against the Wnt pathway inhibitor. Collectively, this research highlighted the potential of an alternative treatment targeting Wnt/Beta Catenin signaling pathway using whole genome sequencing, providing a new idea for the treatment of colorectal cancer. In addition, high expression of long non-coding RNA small nucleolar RNA host genes (lncRNA SNHGs) was revealed to be positively associated with poor CRC prognosis by Luo et al. Thus, lncRNA SNHG could serve as a potential prognostic indicator and therapeutic target for CRC.
In summary, the Research Topic “Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy” collects studies focused on finding novel biomarkers and therapeutic targets in various gynecological and gastrointestinal cancers. The articles in this Research Topic highlight important, interrelated Research Topic and will hopefully serve as a catalyst for further studies that pave the way for developing novel targeting therapeutic strategies for cancers and overcoming therapeutic resistance. Ultimately, we trust that these efforts may eventually help improve survival outcomes and prognoses for gynecological and gastrointestinal cancer patients in the future.
Author contributions
LZ and JZ contributed to the writing and reviewing of this editorial. All authors contributed to the article and approved the submitted version.
Funding
This work was mainly supported by grants from Fundamental Research Funds for the Central Universities (Grant No. 2682022ZTPY032) and Shenzhen Science and Technology Research and Development Funds (Grant No. JCYJ20210324094612035).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Akram, M., Iqbal, M., Daniyal, M., and Khan, A. U. (2017). Awareness and current knowledge of breast cancer. Biol. Res. 50 (1), 33. doi:10.1186/s40659-017-0140-9
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., et al. (2020). Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol. 84, 106535. doi:10.1016/j.intimp.2020.106535
Ciou, H. H., Lee, T. H., Wang, H. C., Ding, Y. R., Tseng, C. J., Wang, P. H., et al. (2022). Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer. Transl. Res. 243, 21–32. doi:10.1016/j.trsl.2021.12.002
Davern, M., and Lysaght, J. (2020). Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. Cancer Lett. 495, 89–99. doi:10.1016/j.canlet.2020.09.014
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., and Wallace, M. B. (2019). Colorectal cancer. Lancet 394 (10207), 1467–1480. doi:10.1016/S0140-6736(19)32319-0
Ge, W., Goga, A., He, Y., Silva, P. N., Hirt, C. K., Herrmanns, K., et al. (2022). miR-802 suppresses acinar-to-ductal reprogramming during early pancreatitis and pancreatic carcinogenesis. Gastroenterology 162 (1), 269–284. doi:10.1053/j.gastro.2021.09.029
Issa, I. A., and Noureddine, M. (2017). Colorectal cancer screening: An updated review of the available options. World J. Gastroenterol. 23 (28), 5086–5096. doi:10.3748/wjg.v23.i28.5086
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., et al. (2021). Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin. Cancer Biol. 77, 144–166. doi:10.1016/j.semcancer.2021.08.011
Mertz, T. M., Collins, C. D., Dennis, M., Coxon, M., and Roberts, S. A. (2022). APOBEC-induced mutagenesis in cancer. Annu. Rev. Genet. 56, 229–252. doi:10.1146/annurev-genet-072920-035840
Murphy, N., Jenab, M., and Gunter, M. J. (2018). Adiposity and gastrointestinal cancers: Epidemiology, mechanisms and future directions. Nat. Rev. Gastroenterol. Hepatol. 15 (11), 659–670. doi:10.1038/s41575-018-0038-1
Keywords: breast cancer, pancreatic adenocarcinoma, colorectal cancer, prognosis, molecular mechanisms, targeted therapy
Citation: Zhang L, Wang G, Zhu L, Wei W and Zhang J (2023) Editorial: Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy. Front. Mol. Biosci. 10:1167337. doi: 10.3389/fmolb.2023.1167337
Received: 16 February 2023; Accepted: 24 February 2023;
Published: 03 March 2023.
Edited by:
William C. Cho, QEH, Hong Kong SAR, ChinaReviewed by:
Teresa Rubio-Tomás, University of Crete, GreeceCopyright © 2023 Zhang, Wang, Zhu, Wei and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lan Zhang, emhhbmdsYW54XzlAMTI2LmNvbQ==; Jin Zhang, emhhbmdqaW4xOTg5QHN6dS5lZHUuY24=